Table 4 Overview of detected mutations in AML blasts and response outcome

From: Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome

Gene

Mutation

Responders (CR/PR) (%)

KRAS

G12D/V/A, G13D/A

3/6 (50)

NRAS

G13D/V/A, Q61H

0/2 (0)

NPM1

W288C

0/4 (0)

IDH2

R140L/G

1/3 (33)

JAK2

V617F

2/2 (100)

MPL-2

W515L/X

0/2 (0)

DNMT3a

R882C/H

0/2 (0)

FLT3

ITD

0/1 (0)

Back to article page